Optune with chemo and immunotherapy for new glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a new diagnosis of glioblastoma (a type of brain tumor).
- You have already completed standard radiation and chemotherapy (temozolomide) after surgery.
- You have recovered well from brain surgery (biopsy, partial, or full removal are okay).
- You have not had a drug that boosts your immune system (like PD-1/PD-L1 inhibitors) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
This study follows patients with newly diagnosed glioblastoma who are receiving maintenance chemotherapy and starting treatment with the Optune device. It aims to see how well the device works in routine care.
This trial tests whether wearing a device called Optune (which uses electric fields to slow cancer growth) before surgery helps people with glioblastoma. It is for patients who are fairly active and plan to have standard tumor removal and radiation therapy afterward.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.